{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:27:39Z","timestamp":1792452459540,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","annalsthoracicsurgery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.athoracsur.2024.03.035","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T09:41:09Z","timestamp":1713174069000},"page":"1177-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung Cancer\u2014Current Evidence and Future Directions"],"prefix":"10.1016","volume":"118","author":[{"given":"Muhammad H.","family":"Shahzad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-6120","authenticated-orcid":false,"given":"Peter J.","family":"Kneuertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2024.03.035_bib1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib5","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2007.14.1226","article-title":"Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline","volume":"25","author":"Pisters","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib6","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.athoracsur.2012.03.031","article-title":"Tumor recurrence after complete resection for non-small cell lung cancer","volume":"93","author":"Taylor","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib7","first-page":"242","article-title":"Recurrence after surgery in patients with NSCLC","volume":"3","author":"Uramoto","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib9","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib11","first-page":"CD011430","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer","volume":"2015","author":"Burdett","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib12","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.21.01589","article-title":"Preoperative and postoperative systemic therapy for operable non\u2013small-cell lung cancer","volume":"40","author":"Chaft","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib15","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib16","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups","volume":"26","author":"Strauss","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.03.035_bib17","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1200\/jco.2011.29.15_suppl.7015","article-title":"Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633","volume":"29","author":"Strauss","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib18","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A\u00a0randomized trial of adjuvant chemotherapy with uracil\u2013tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib19","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1200\/JCO.2005.09.017","article-title":"Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non\u2013small-cell lung cancer","volume":"23","author":"Hamada","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/JTO.0b013e3181bbf1f2","article-title":"Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage ia non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials","volume":"4","author":"Hamada","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib22","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.athoracsur.2021.04.108","article-title":"Adjuvant chemotherapy for high-risk pathologic stage I non-small cell lung cancer","volume":"113","author":"Tsutani","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib23","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib24","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.03.035_bib26","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S1556-0864(23)00338-6","article-title":"Abstract 840: Neoadjuvant nivolumab (N)\u00a0+ platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816. European Lung Cancer Conference; March 30, 2023; Copenhagen, Denmark","volume":"18","author":"Forde","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.03.035_bib29","doi-asserted-by":"crossref","first-page":"CT005","DOI":"10.1158\/1538-7445.AM2023-CT005","article-title":"Abstract CT005: AEGEAN: a phase 3 trial of neoadjuvant durvalumab\u00a0+ chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC","volume":"83","author":"Heymach","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.03.035_bib30","article-title":"Perioperative toripalimab\u00a0+ platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Wu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemo-immunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41586-022-05672-3","article-title":"Single-cell spatial landscapes of\u00a0the lung tumour immune microenvironment","volume":"614","author":"Sorin","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib34","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall survival and biomarker analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib35","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 7","key":"10.1016\/j.athoracsur.2024.03.035_bib36","doi-asserted-by":"crossref","first-page":"S1373","DOI":"10.1016\/j.annonc.2021.10.017","article-title":"10 Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC","volume":"32","author":"Kris","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib37","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib38","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib40","article-title":"Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"10","author":"Casarrubios","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.491","article-title":"Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial","volume":"11","author":"Laza-Briviesca","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib42","article-title":"Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity","volume":"11","author":"Sorin","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib43","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: the phase 2 NeoCOAST Platform Trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib44","article-title":"Tumour extracellular vesicles induce neutrophil extracellular traps to promote lymph node metastasis","volume":"12","author":"Su","year":"2023","journal-title":"J\u00a0Extracell Vesicles"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.03.035_bib51","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/JCO.2023.41.16_suppl.8521","article-title":"Clinical outcomes with neoadjuvant nivolumab (N)\u00a0+ chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial","volume":"41","author":"Spicer","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.athoracsur.2024.03.035_bib52","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO)\u00a0+ platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.21037\/tlcr-20-509","article-title":"Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer","volume":"10","author":"Huynh","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib54","first-page":"1","article-title":"Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy","volume":"42","author":"Provencio","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib55","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100016","article-title":"Video-assisted thoracoscopic or open lobectomy in early-stage lung cancer","volume":"1","author":"Lim","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2022.01.019","article-title":"Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer","volume":"165","author":"Wu","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib58","article-title":"Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"13","author":"Zeng","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib59","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jtcvs.2022.10.007","volume":"165","author":"Rusch","year":"2023","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib60","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.athoracsur.2020.11.022","article-title":"Multimodal prehabilitation for lung cancer surgery: a randomized controlled trial","volume":"112","author":"Ferreira","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib61","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bja.2021.12.007","article-title":"Prehabilitation, enhanced recovery after surgery, or both? A narrative review","volume":"128","author":"Gillis","year":"2022","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib62","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1053\/j.jvca.2021.02.049","article-title":"Prehabilitation in thoracic cancer surgery: from research to standard of care","volume":"35","author":"Minnella","year":"2021","journal-title":"J\u00a0Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib63","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.athoracsur.2021.05.081","article-title":"The case for periadjuvant therapy in early-stage lung cancer","volume":"113","author":"Spicer","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib64","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamasurg.2018.1645","article-title":"Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: a randomized clinical trial","volume":"153","author":"Minnella","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-018-5232-6","article-title":"Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation","volume":"19","author":"van Rooijen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib66","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/ALN.0000000000000393","article-title":"Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer","volume":"121","author":"Gillis","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cllc.2022.05.004","article-title":"Neoadjuvant prehabilitation therapy for locally advanced non\u2013small-cell lung cancer: optimizing outcomes throughout the trajectory of care","volume":"23","author":"Schmid","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib68","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1007\/s00520-021-06161-5","article-title":"Effects of preoperative nutrition and multimodal prehabilitation on functional capacity and postoperative complications in surgical lung cancer patients: a systematic review","volume":"29","author":"Ferreira","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.athoracsur.2024.03.035_bib69","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00262-022-03169-6","article-title":"Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors","volume":"71","author":"Shaikh","year":"2022","journal-title":"Cancer Immunol Immunother"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497524002807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497524002807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:54:14Z","timestamp":1732276454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497524002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0003497524002807"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2024.03.035","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung Cancer\u2014Current Evidence and Future Directions","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2024.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Society of Thoracic Surgeons. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}